Megastril

Megestrol Acetate, the active ingredient in Megastril, is a progestin presented as an oral formulation for systemic use. It is employed to stimulate appetite in patients with cachexia and to treat certain hormone‑sensitive cancers such as advanced breast and endometrial carcinoma.

GNH USA supplies Megastril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality and regulatory compliance across markets and providing reliable logistics for global distribution.

Megestrol Acetate is a progestin used in hormone‑dependent conditions and cachexia.

- Cachexia: improves appetite and promotes weight gain in patients with cancer‑related or AIDS‑related wasting. - Advanced breast cancer: provides antineoplastic activity in hormone‑responsive tumors. - Endometrial cancer: used as hormonal therapy for advanced or recurrent disease.

Megestrol Acetate may be associated with a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Weight gain: increased adipose tissue and fluid retention. - Nausea: mild to moderate gastrointestinal discomfort. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Adrenal suppression: reduced cortisol production. - Severe allergic reaction: anaphylaxis or Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor weight: assess for excessive gain or edema. - Check blood glucose: screen for hyperglycemia, especially in diabetic patients. - Evaluate lipid profile: periodic testing for dyslipidemia. - Assess for thrombotic risk: avoid in patients with history of clotting disorders. - Review adrenal function: consider cortisol testing if long‑term therapy is planned. - Store at ambient temperature: keep below 25°C in original container, protect from moisture.

Megestrol Acetate can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Anticoagulants: increased risk of thrombosis. - CYP3A4 inducers (e.g., rifampin): may reduce plasma levels. - Glucocorticoids: additive adrenal suppression.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: potential for hyperglycemia. - Lipid‑lowering drugs: may alter lipid profile. - Hormonal therapies: possible antagonistic effects.